A Phase 1 interventional study of MK-2060 and Placebo in End-Stage Renal Disease, End-Stage Kidney Disease and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 10 in phase 1, and was the 9th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was intended as a three-part study of MK-2060 in participants with chronic and/or end-stage kidney disease (Parts 2 and 3 were not initiated due to reasons not related to safety). The purpose of Part 1 of the study was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single subcutaneous dose of MK-2060 in stage 4 chronic kidney disease (CKD4) [Part2 was intended to evaluate multiple subcutaneous doses in CKD4 participants and Part 3 was intended to evaluate a single subcutaneous dose of MK-2060 in participants with end-stage kidney disease (ESRD)]. The primary hypothesis for Part 1 was that the true geometric mean of the area under the concentration-time curve from 0 to infinity (AUC0-inf) after a single-dose of MK-2060 in adult CKD4 participants would be at least 11300 nM*hr.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received MK-2060 30 mg administered as a single subcutaneous dose on Day 1.
Biological: MK-2060
Participants received placebo (normal saline) administered as a single subcutaneous dose on Day 1.
Drug: Placebo
MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
Normal saline administered subcutaneously
Part 1: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)
Bleeding related AEs will include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.
Time frame: Up to approximately 104 days
Part 2: Number of Participants Who Experience One or More Bleeding Related AEs
Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.
Time frame: Up to approximately 144 days
Part 3: Number of Participants Who Experience One or More Bleeding Related AEs
Bleeding related AEs will include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.
Time frame: Up to approximately 104 days
Part 1: Number of Participants Who Experience One or More AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 104 days
Part 2: Number of Participants Who Experience One or More AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 144 days
Part 3: Number of Participants Who Experience One or More AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 104 days
Part 1: Number of Participants Who Discontinue Study Treatment to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 104 days
Part 2: Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 144 days
Part 3: Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 104 days
Part 1: Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) of MK-2060
Blood was collected to determine the AUC0-inf of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Part 2: AUC0-inf of MK-2060
Blood was to be collected at pre-specified time points to determine the AUC0-inf of MK-2060 in plasma.
Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose
Part 3: AUC0-inf of MK-2060
Blood was to be collected at pre-specified time points to determine the AUC0-inf of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose
Part 1: Area Under the Concentration-Time Curve From Time 0 to 168 Hours (AUC0-168) of MK-2060
Blood was collected to determine the AUC0-168 of MK-2060 in plasma.
Time frame: Pre-dose, 1, 12, 24, 48, 120, and 168 hours post-dose
Part 2: AUC0-168 of MK-2060
Blood was to be collected at pre-specified time points to determine the AUC0-168 of MK-2060 in plasma from 0 to 168 hours.
Time frame: Pre-dose, 24, 72, and 168 hours post-dose
Part 3: AUC0-168 of MK-2060
Blood was to be collected at pre-specified time points to determine the AUC0-168 of MK-2060 in plasma from 0 to 168 hours.
Time frame: Pre-dose, 1, 12, 24, 48, 120, and 168 hours post-dose
Part 1: Maximum Plasma Concentration (Cmax) of MK-2060
Blood was collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Part 2: Cmax of MK-2060
Blood was to be collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.
Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose
Part 3: Cmax of MK-2060
Blood was to be collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose
Part 1: Plasma Concentration at 168 Hours (C168) of MK-2060
Blood was collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.
Time frame: 168 hours post-dose
Part 2: C168 of MK-2060
Blood was to be collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.
Time frame: 168 hours post-dose
Part 3: C168 of MK-2060
Blood was to be collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.
Time frame: 168 hours post-dose
Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-2060
Blood was collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Part 2: Tmax of MK-2060
Blood was to be collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.
Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose
Part 3: Tmax of MK-2060
Blood was to be collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose
Part 1: Terminal Half Life (t1/2) of MK-2060
Blood was collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Part 2: t1/2 of MK-2060
Blood was to be collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.
Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose
Part 3: t1/2 of MK-2060
Blood was to be collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose
Part 1: Apparent Total Clearance (CL/F) of MK-2060
Blood was collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Part 2: CL/F of MK-2060
Blood was to be collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.
Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose
Part 3: CL/F of MK-2060
Blood was to be collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose
Part 1: Apparent Volume of Distribution (Vz/F) of MK-2060
Blood was collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Part 2: Vz/F of MK-2060
Blood was to be collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma
Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose
Part 3: Vz/F of MK-2060
Blood was to be collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma
Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose
Part 1: Mean Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060
Blood was collected at pre-specified time points to determine the aPTT of MK-2060 in plasma. Positive and negative scores indicate increases and decreases, respectively, in aPTT compared to baseline.
Time frame: Day 1 (1 hr and 12 hrs postdose) and Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and Post Study (Day 90)
Part 2: Percent Change From Baseline in aPTT of MK-2060
Blood was to be collected at pre-specified time points to determine the aPTT of MK-2060 in plasma.
Time frame: Day 1 (1 hr and 12 hrs postdose) and Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and Post Study (Day 90)
Part 3: Percent Change From Baseline in aPTT of MK-2060
Blood was to be collected at pre-specified time points to determine the aPTT of MK-2060 in plasma.
Time frame: Day 1 (1 hr and 12 hrs postdose) and Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and Post Study (Day 90)
Adult participants with stage 4 chronic kidney disease (CKD4) were recruited.
| Milestone | MK-2060 30 mg | Placebo |
|---|---|---|
| Started | 11 | 3 |
| Completed | 11 | 3 |
| Not completed | 0 | 0 |
Bleeding related AEs will include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.
| Participants | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) | 0 | 0 |
Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.
No measurements were reported for this outcome.
Bleeding related AEs will include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
| Participants | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Number of Participants Who Experience One or More AEs | 5 | 2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
| Participants | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Number of Participants Who Discontinue Study Treatment to an AE | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
No measurements were reported for this outcome.
Blood was collected to determine the AUC0-inf of MK-2060 in plasma.
| hr*nM | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) of MK-2060 | 14300 ± 40.9 | — |
Blood was to be collected at pre-specified time points to determine the AUC0-inf of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was to be collected at pre-specified time points to determine the AUC0-inf of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was collected to determine the AUC0-168 of MK-2060 in plasma.
| hr*nM | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Area Under the Concentration-Time Curve From Time 0 to 168 Hours (AUC0-168) of MK-2060 | 727 ± 103.3 | — |
Blood was to be collected at pre-specified time points to determine the AUC0-168 of MK-2060 in plasma from 0 to 168 hours.
No measurements were reported for this outcome.
Blood was to be collected at pre-specified time points to determine the AUC0-168 of MK-2060 in plasma from 0 to 168 hours.
No measurements were reported for this outcome.
Blood was collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.
| nM | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Maximum Plasma Concentration (Cmax) of MK-2060 | 11.3 ± 38.8 | — |
Blood was to be collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was to be collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.
| nM | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Plasma Concentration at 168 Hours (C168) of MK-2060 | 7.19 ± 79.7 | — |
Blood was to be collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was to be collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.
| hours | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-2060 | 312.82 (143.67 to 648.88) | — |
Blood was to be collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was to be collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.
| hours | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Terminal Half Life (t1/2) of MK-2060 | 677 ± 26.3 | — |
Blood was to be collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was to be collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.
| Liters/hour | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Apparent Total Clearance (CL/F) of MK-2060 | 0.0141 ± 40.9 | — |
Blood was to be collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was to be collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma
| Liters | MK-2060 30 mg | Placebo |
|---|---|---|
| Part 1: Apparent Volume of Distribution (Vz/F) of MK-2060 | 13.8 ± 39.6 | — |
Blood was to be collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma
No measurements were reported for this outcome.
Blood was to be collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma
No measurements were reported for this outcome.
Blood was collected at pre-specified time points to determine the aPTT of MK-2060 in plasma. Positive and negative scores indicate increases and decreases, respectively, in aPTT compared to baseline.
| Mean fold change from baseline | MK-2060 30 mg | Placebo |
|---|---|---|
| Day 1: 1 Hour Postdose | 1.047 ± 0.028 | 0.977 ± 0.037 |
| Day 1: 12 Hours Postdose | 1.044 ± 0.03 | 0.994 ± 0.017 |
| Day 2 | 1.05 ± 0.021 | 0.971 ± 0.02 |
| Day 3 | 1.137 ± 0.04 | 1.032 ± 0.033 |
| Day 6 | 1.219 ± 0.059 | 1.075 ± 0.081 |
| Day 8 | 1.202 ± 0.059 | 1.08 ± 0.093 |
| Day 11 | 1.157 ± 0.063 | 1.08 ± 0.084 |
| Day 14 | 1.128 ± 0.042 | 1.102 ± 0.114 |
| Day 21 | 1.114 ± 0.037 | 1.01 ± 0.075 |
| Day 28 | 1.07 ± 0.048 | 1.012 ± 0.049 |
| Day 60 | 1.101 ± 0.038 | 1.053 ± 0.115 |
| Post Study (Day 90) | 1.026 ± 0.044 | 1.129 ± 0.064 |
Blood was to be collected at pre-specified time points to determine the aPTT of MK-2060 in plasma.
No measurements were reported for this outcome.
Blood was to be collected at pre-specified time points to determine the aPTT of MK-2060 in plasma.
No measurements were reported for this outcome.
Collected over Up to approximately 104 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-2060 30 mg | 0/11 (0%) | 2/11 (18.2%) | 5/11 (45.5%) |
| Placebo | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Event | MK-2060 30 mg | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/11 | 0/3 |
| Cardiac failure congestiveCardiac disorders | 1/11 | 0/3 |
| Acute kidney injuryRenal and urinary disorders | 1/11 | 0/3 |
| Event | MK-2060 30 mg | Placebo |
|---|---|---|
| Eustachian tube obstructionEar and labyrinth disorders | 0/11 | 1/3 |
| Occult blood positiveInvestigations | 0/11 | 1/3 |
| White blood cell count increasedInvestigations | 0/11 | 1/3 |
| Vertigo positionalEar and labyrinth disorders | 1/11 | 0/3 |
| Abdominal painGastrointestinal disorders | 1/11 | 0/3 |
| NauseaGastrointestinal disorders | 1/11 | 0/3 |
| VomitingGastrointestinal disorders | 1/11 | 0/3 |
| AstheniaGeneral disorders | 1/11 | 0/3 |
| Injection site erythemaGeneral disorders | 1/11 | 0/3 |
| Respiratory tract infectionInfections and infestations | 1/11 | 0/3 |
| Age, Continuous(Years) | MK-2060 30 mg | Placebo | Total |
|---|---|---|---|
| Mean | 71.1 ± 9.4 | 59.0 ± 17.4 | 68.5 ± 11.9 |
| Sex: Female, Male(Participants) | MK-2060 30 mg | Placebo | Total |
|---|---|---|---|
| Female | 7 | 2 | 9 |
| Male | 4 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | MK-2060 30 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 10 | 2 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MK-2060 30 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 0 | 6 |
| White | 5 | 3 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Feb 2023 to primary completion in Aug 2024, 18 months.
Results were first posted in Sep 2025, 1 year after primary completion.
Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 18 months is above that.
Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-2060